Enzon Pharmaceuticals, Inc. Sustainability Profile
Enzon Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 1981, the company has established itself as a leader in the development of innovative therapies, particularly in the fields of oncology and rare diseases. Enzon is renowned for its proprietary PEGylation technology, which enhances the efficacy and safety of therapeutic proteins. With a strong focus on research and development, Enzon Pharmaceuticals has achieved significant milestones, including the successful launch of several unique products that address unmet medical needs. The company’s commitment to advancing patient care has solidified its position in the market, making it a respected name among healthcare professionals and patients alike. Through its dedication to innovation, Enzon continues to contribute to the evolving landscape of biopharmaceuticals.
DitchCarbon Score
How does Enzon Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Enzon Pharmaceuticals, Inc.'s score of 23 is lower than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Enzon Pharmaceuticals, Inc.'s reported carbon emissions
Enzon Pharmaceuticals, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to address carbon emissions at this time. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and climate action, often setting science-based targets to reduce their carbon footprints. However, without specific data or commitments from Enzon Pharmaceuticals, it is unclear how they align with these industry trends. As the company continues to operate, it may consider developing a strategy to measure and report its emissions, as well as setting reduction targets to contribute to global climate efforts.
How Carbon Intensive is Enzon Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Enzon Pharmaceuticals, Inc.'s Location?
Enzon Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Enzon Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
